Drugging the undruggable RAS: Mission Possible?

被引:0
|
作者
Adrienne D. Cox
Stephen W. Fesik
Alec C. Kimmelman
Ji Luo
Channing J. Der
机构
[1] Lineberger Comprehensive Cancer Center,
[2] University of North Carolina at Chapel Hill,undefined
[3] Vanderbilt University School of Medicine,undefined
[4] Dana-Farber Cancer Institute,undefined
[5] National Cancer Institute,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Attempts to target RAS pharmaceutically have not yet yielded small molecules with sufficient potency and drug-like characteristics to be useful, but additional approaches are underway.Inhibitors of RAS membrane interaction and subcellular localization remain attractive targets for therapeutic intervention. In this regard, recent discoveries of functionally relevant post-translational modifications of RAS, such as phosphorylation and ubiquitylation, suggest new opportunities to block RAS function.Inhibitors of RAS effector signalling are currently centred on the RAF–MEK–ERK and PI3K–AKT–TOR pathways, with many inhibitors of components of these two pathways under clinical evaluation. The less well-studied effector pathways that lead to activation of RAL and RAC small GTPases are also promising targets.Despite some setbacks owing to issues of reproducibility, functional screens for synthetic lethal interactors with oncogenic RAS remain an attractive approach to identify novel drug targets for RAS-driven cancers.RAS-driven cancers become efficient scavengers of nutrients and may rely on pathways such as autophagy and macropinocytosis. Furthermore, oncogenic KRAS has a crucial role in altering tumour metabolism, including rewiring of both glucose- and glutamine-dependent metabolic pathways. These alterations could provide the opportunity for novel therapeutic interventions.Inhibitors of RAS membrane interaction and subcellular localization remain attractive targets for therapeutic intervention. In this regard, recent discoveries of functionally relevant post-translational modifications of RAS, such as phosphorylation and ubiquitylation, suggest new opportunities to block RAS function.RAS-driven cancers become efficient scavengers of nutrients and may rely on pathways such as autophagy and macropinocytosis. Furthermore, oncogenic KRAS has a crucial role in altering tumour metabolism, including rewiring of both glucose- and glutamine-dependent metabolic pathways. These alterations could provide the opportunity for novel therapeutic interventions.
引用
收藏
页码:828 / 851
页数:23
相关论文
共 50 条
  • [41] Drugging the Master Regulator TP53 in Cancer: Mission Possible?
    Blandino, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (14) : 1595 - +
  • [42] Drugging the Next Undruggable KRAS Allele-Gly12Asp
    Zheng, Qinheng
    Peacock, D. Matthew
    Shokat, Kevan M.
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (04) : 3119 - 3122
  • [43] Drugging the undruggable: gabapentin, pregabalin and the calcium channel α2δ subunit
    Offord, James
    Isom, Lori L.
    CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2016, 51 (04) : 246 - 256
  • [44] Drugging "undruggable" genes for cancer treatment: Are we making progress?
    Duffy, Michael J.
    Crown, John
    INTERNATIONAL JOURNAL OF CANCER, 2021, 148 (01) : 8 - 17
  • [45] Drugging the Undruggable: Therapeutic Potential of Targeting Protein Tyrosine Phosphatases
    Zhang, Zhong-Yin
    ACCOUNTS OF CHEMICAL RESEARCH, 2017, 50 (01) : 122 - 129
  • [46] Drugging RAS: Know the enemy
    Papke, Bjoern
    Der, Channing J.
    SCIENCE, 2017, 355 (6330) : 1158 - 1163
  • [47] Drugging the undruggable: Lessons learned from protein phosphatase 2A
    Taylor, Derek
    Narla, Goutham
    CANCER RESEARCH, 2020, 80 (16)
  • [48] Drugging the "undruggable" DNA-binding domain of STAT3
    Zhang, Jian-Ting
    Liu, Jing-Yuan
    ONCOTARGET, 2016, 7 (41) : 66324 - 66325
  • [49] PGE2 receptors in detrusor muscle: Drugging the undruggable for urgency
    Hou, Ruida
    Yu, Ying
    Jiang, Jianxiong
    BIOCHEMICAL PHARMACOLOGY, 2021, 184